Study of a new drug plus chemo for EGFR/ALK/ROS1 lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called AK112 combined with platinum-based chemotherapy for people with non-small cell lung cancer that has a specific gene change (EGFR, ALK, or ROS1) and has stopped responding to initial treatment. The goal is to see if this combination can help when the first targeted therapy no longer works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- You must be in good enough health to be up and about (ECOG score 0 or 1).
- You must have non-small cell lung cancer with an EGFR, ALK, or ROS1 gene change found by a genetic test.
- Your cancer must have gotten worse after first-line treatment: for EGFR, after osimertinib; for ALK, after alectinib; for ROS1, after crizotinib or entrectinib.
- You cannot have received any immunotherapy before (like PD-1 or CTLA-4 blockers).
- You must not have had other cancer treatments for advanced disease except for the first-line targeted therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, AK112, combined with chemotherapy for people with advanced non-squamous non-small cell lung cancer that has spread to the lining of the lung (malignant pleural effusion). The goal is to see if this combination helps shrink tumors and improve outcomes.
This trial tests a new immunotherapy drug, AK112, for people with a specific type of lung cancer (non-squamous) that has certain genetic changes and has stopped responding to targeted therapy. The goal is to see if AK112 can help when targeted treatments no longer work.
This trial tests a combination of two experimental drugs, AK146D1 and AK112, for people with advanced non-small cell lung cancer that cannot be removed by surgery or treated with standard chemo-radiation. It aims to find out if this combination can shrink tumors or slow cancer growth.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This Phase 1 trial tests APG-2449, a new drug, in people with advanced solid tumors—especially certain lung cancers that have ALK or ROS1 gene fusions. Because it’s an early safety-and-dose study, it may help learn how well the drug works and what doses are safe.
This trial tests a new targeted drug (PLB1004) combined with two chemotherapy drugs for people with a specific EGFR gene change in their non-small cell lung cancer. The goal is to see if this combination works better than current treatments, both for advanced cancer and for cancer that can be surgically removed.
Hear when a new Efficacy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.